Prelude Capital Management’s Royalty Pharma RPRX Stock Holding History

Prelude Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Sell	4,305 -8,840	-67%	-$460K	0.02%	891
2026 Q1	$631K	Buy	+13,145	New	+$576K	0.05%	425
2025 Q3	–	Sell	-26,812	Closed	-$966K	–	1342
2025 Q2	$966K	Buy	26,812 +971	+4%	+$32.2K	0.09%	267
2025 Q1	$804K	Buy	+25,841	New	+$819K	0.06%	362
2024 Q2	–	Sell	-22,866	Closed	-$694K	–	1457
2024 Q1	$694K	Buy	+22,866	New	+$674K	0.04%	499
2023 Q3	–	Sell	-15,944	Closed	-$490K	–	1323
2023 Q2	$490K	Buy	15,944 +944	+6%	+$32K	0.03%	470
2023 Q1	$540K	Hold	15,000	–	–	0.03%	436
2022 Q4	$593K	Buy	+15,000	New	+$626K	0.03%	506
2022 Q2	–	Sell	-9,131	Closed	-$356K	–	2021
2022 Q1	$356K	Buy	+9,131	New	+$359K	0.01%	1004
2021 Q4	–	Sell	-6,560	Closed	-$237K	–	2214
2021 Q3	$237K	Buy	+6,560	New	+$255K	0.01%	1266

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's RPRX Position: Q2 2026 in Review

Prelude Capital Management reduced its Royalty Pharma (RPRX) stake by 67% in Q2 2026, selling an estimated $460K and leaving 4,305 shares worth $241K. The position accounts for 0.02% of the portfolio, ranked #891.

Prelude Capital Management first reported a position in RPRX in Q3 2021 and has held it in 10 quarters since. The position peaked at $966K in Q2 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Prelude Capital Management held 4,305 shares of Royalty Pharma worth $241K as of Q2 2026.
Prelude Capital Management sold 8,840 Royalty Pharma shares in Q2 2026, an estimated $460K.
Royalty Pharma made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #891 holding.
Prelude Capital Management first reported a position in Royalty Pharma in Q3 2021 and has held it in 10 quarters since.
Prelude Capital Management's Royalty Pharma position peaked at $966K in Q2 2025.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.